Ta del av utdrag från ett inspelat webbinarium med professor Usha Chakravarthy, som ägde rum den 21a januari 2021, med Novartis Finland som värd. Under mötet presenterades den senaste kliniska forskningen kring fluktuationer i retinal vätska vid våt AMD. 

 

 

 

Referenser
Real-world impact of macular fluid volume fluctuations on visual acuity following two years of anti-VEGF therapy in eyes with nAMD:
  • Dugel ym. HAWK and HARRIER Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 128(1):89-99, 2021. doi: 10.1016/j.ophtha.2020.06.028
  • Evans ym. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol. 138(10):1043-1051, 2020. doi: 10.1001/jamaophthalmol.2020.3001
  • Chakravarthy ym. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet 382(9900): 1258-1267, 2013. doi: 10.1016/S0140-6736(13)61501-9
Clinical data suggests that visual acuity is worse when fluid fluctuations are worse. Are these findings also replicable in real world data? And does the location of fluid in retina tissue compartments matter?: 
  • Chakravarthy ym. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond) 2021, Online ahead of print. doi: 10.1038/s41433-020-01354-4

Denna inspelning har redigerats från originalet för att uppfylla lokala bestämmelser och riktlinjer. 

0
Betygsätt sidan
SE2104154893 (15 april 2021)
×

Ask Speakers

×

Medical Information Request